Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
Chiara Cremolini(University of Pisa), Daniele Santini(Policlinico Umberto I), Francesco Pantano(Università Campus Bio-Medico), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Adele Busico(Fondazione IRCCS Istituto Nazionale dei Tumori), Carlo Barone(Università Cattolica del Sacro Cuore), Emiliano Tamburini(Ospedale Infermi di Rimini), Francesca Bergamo(Istituto Oncologico Veneto), Marzia Del Re(Saint Camillus International University of Health and Medical Sciences), Sara Lonardi(Istituto Oncologico Veneto), Domenico Corsi(Ospedale San Carlo), Gianluca Masi(University of Pisa), Francesca Pucci(University of Parma), Daniele Rossini(Azienda Ospedaliera Universitaria Pisana), Elena Conca(Fondazione IRCCS Istituto Nazionale dei Tumori), Nicoletta Pella(University of Udine), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Romano Danesi(University of Milan), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Emanuela Dell’Aquila(Università Campus Bio-Medico), C. Barbara(Presidio Ospedaliero), Eleonora Rofi(University of Pisa)
Cited by 418
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
|Journal of Clinical Oncology|2007|1.2k